Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.

Rossignol DP, Wong N, Noveck R, Lynn M.

Innate Immun. 2008 Dec;14(6):383-94. doi: 10.1177/1753425908099173.

PMID:
19039062
2.

Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.

Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, Moran J, Lynn M.

Antimicrob Agents Chemother. 2004 Sep;48(9):3233-40.

3.

Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study.

Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M.

J Clin Pharmacol. 2003 Jul;43(7):735-42.

PMID:
12856387
4.
5.

Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.

Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG.

J Infect Dis. 2003 Feb 15;187(4):631-9.

PMID:
12599080
6.

Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].

Lynn M, Wong YN, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, Vargas R, D'Angelo T, Gotzkowsky S, McMahon FG, Wasan KM, Rossignol DP.

J Pharmacol Exp Ther. 2004 Jan;308(1):175-81. Erratum in: J Pharmacol Exp Ther. 2004 Feb;308(2):796.

7.

Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.

Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP.

J Pharmacol Exp Ther. 2003 Mar;304(3):1093-102.

8.
9.

Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.

Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM; Eritoran Sepsis Study Group..

Crit Care Med. 2010 Jan;38(1):72-83. doi: 10.1097/CCM.0b013e3181b07b78. Erratum in: Crit Care Med. 2010 Sep;38(9):1925-6. Multiple investigator names added..

PMID:
19661804
10.

Pharmacokinetics of E5564, a lipopolysaccharide antagonist, in patients with impaired hepatic function.

Liang E, Wong YN, Allen I, Kao R, Marino M, DiLea C.

J Clin Pharmacol. 2003 Dec;43(12):1361-9.

PMID:
14615472
11.

E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes.

Czeslick E, Struppert A, Simm A, Sablotzki A.

Inflamm Res. 2006 Nov;55(11):511-5.

PMID:
17122970
12.

A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia.

Bunnell E, Lynn M, Habet K, Neumann A, Perdomo CA, Friedhoff LT, Rogers SL, Parrillo JE.

Crit Care Med. 2000 Aug;28(8):2713-20.

PMID:
10966240
13.

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.

Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz DA.

Am J Physiol Lung Cell Mol Physiol. 2005 Aug;289(2):L329-37.

14.

Inhibition of endotoxin response by synthetic TLR4 antagonists.

Hawkins LD, Christ WJ, Rossignol DP.

Curr Top Med Chem. 2004;4(11):1147-71. Review.

PMID:
15279606
15.

In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.

Ehrentraut S, Lohner R, Schwederski M, Ehrentraut H, Boehm O, Noga S, Langhoff P, Baumgarten G, Meyer R, Knuefermann P.

Shock. 2011 Dec;36(6):613-20. doi: 10.1097/SHK.0b013e318235805f.

PMID:
22089127
16.

Disposition of a synthetic analogue of lipid A (E5564) in rats.

Kaneko K, Ueda R, Nemoto H, Iijima H, Yoshimura T.

Xenobiotica. 2003 Mar;33(3):323-39.

PMID:
12637248
17.

A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.

Bennett-Guerrero E, Grocott HP, Levy JH, Stierer KA, Hogue CW, Cheung AT, Newman MF, Carter AA, Rossignol DP, Collard CD.

Anesth Analg. 2007 Feb;104(2):378-83.

PMID:
17242095
18.

Quantitative determination of a potent lipopolysaccharide antagonist, E5564, in rat and dog plasma by high-performance liquid chromatography with fluorescence detection.

Kaneko K, Ueda R, Kikuchi K, Sano Y, Yoshimura T.

J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):67-75.

PMID:
10676985
19.

Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.

Yang H, Daun JM, Rose JR, Christ WJ, Gusovsky F, Chow JC.

J Endotoxin Res. 2000;6(6):447-52.

PMID:
11521069
20.

LPS binding protein does not participate in the pharmacokinetics of E5564.

Kaneko K, Ueda R, Kawata T, Ishizaka S, Yoshimura T.

J Endotoxin Res. 2004;10(3):185-94.

PMID:
15198853

Supplemental Content

Support Center